In these cases, talk to your prescribing physician about whether to continue your scheduled dose increase or hold at the current dose until the UTI resolves
In November 2025, however, President Trump announced that Zepbound and other GLP-1s would be covered by Medicare starting as early as April 2026
Provider-to-Patient Approach: Unlike impersonal consumer-based programs, we offer a trusted point of contact and personalized care tailored to your unique needs
A provider may monitor progress, review side effects, evaluate tolerance, and adjust the treatment plan when appropriate
What matters most is not which approach you choose, but that you commit to it consistently, track your response carefully, and work with a qualified provider throughout the process